Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, With No Distribution to Other Organs

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Turn-Biotech-mRNA

More Like This

PR Newswire associated0

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

PR Newswire associated0

FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to Clinic

PR Newswire associated0

Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for its Epigenetic Reprogramming Therapies

Business Wire logo

ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11th International mRNA Health Conference

PR Newswire associated0

Turn Biotechnologies Announces Landmark Study to Assess Effectiveness of ERA™ Therapy in Restoring Bone Marrow

PR Newswire associated0

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

PartitionBio™ awarded grant to exploit its novel biologics shuttle platform for therapeutic nucleic acids delivery

LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches